Back to All Events

Anesthetic and Analgesic Drug Products Advisory Committee

The Committee will discuss a new drug application (NDA 209128) for sufentanil sublingual tablets, submitted by AcelRx Pharmaceuticals, Inc., for the  management of moderate-to-severe acute pain  severe enough to require an opioid analgesic and for which  alternative treatments are inadequate, in adult patients in a medically supervised setting. The Committee will also be asked to discuss risk-benefit considerations and  whether this product  should be approved.